PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Calcineurin Inhibitor Triple Therapy Ranks Highest for Lupus Nephritis Remission

tacrolimusvoclosporinbelimumabobinutuzumabrituximabocrelizumabanifrolumababataceptcalcineurin inhibitorslupus nephritissystemic lupus erythematosusnetwork meta-analysisinduction therapyrenal remission Rheumatology / Immunology

Background Information

Triple therapy with Tacrolimus or Voclosporin excels in lupus nephritis remission.

Lupus nephritis is a severe manifestation of systemic lupus erythematosus requiring effective treatment options to achieve remission and prevent kidney damage. Triple therapy combinations, particularly SOC with Tacrolimus or Voclosporin, effectively induce remission in lupus nephritis, performing better than standard of care alone with similar safety profiles. This analysis suggests calcineurin inhibitors in triple therapy are highly effective for lupus nephritis; however, these results largely pertain to adult population data and may not wholly represent pediatric cases. Triple therapy, especially with Tacrolimus or Voclosporin, shows promise for lupus nephritis remission.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Contreras G, Mechery V, Kota S, Del Castillo Rix D, Bandes M, Dejman A, Zuo Y, Duque JC, Munoz Mendoza J

Citation: Contreras G, Mechery V, Kota S, et al. Network meta-analysis of triple immunosuppressive therapies and standard of care for induction of remission of active lupus nephritis. Lupus. 2026:9612033261474940. doi:10.1177/09612033261474940

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →